Anti-Obesity drugs

The best anti-obesity medication would result in minimum adverse effects and long-term weight loss. Energy balance regulation mechanisms are highly redundant by design, have significant overlap with other physiological processes, and are impacted by social, hedonic, and psychological factors, which reduce the efficacy of pharmacological therapies. Drugs that target metabolic pathways in skeletal muscle, liver, and adipocytes have showed promise in preclinical research, but none have entered clinical development. Recent advances in knowledge of leptin and its upstream pathways in the hypothalamus, as well as peptidergic signaling of hunger and satiety from the gastrointestinal tract mediated by ghrelin, cholecystokinin, peptide YY, and glucagon-like peptide-1, have created new opportunities.



    Related Conference of Anti-Obesity drugs

    June 27-28, 2024

    20th Euro Obesity and Endocrinology Congress

    London, UK
    August 29-30, 2024

    18th International Conference on Obesity Medicine

    Helsinki, Finland
    November 18-19, 2024

    4th World Summit on Obesity and Weight Management

    Paris, France
    November 28-29, 2024

    25th Annual Meet on Obesity and Diet

    Bali, Indonesia

    Anti-Obesity drugs Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in